

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/034519

International filing date: 20 October 2004 (20.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/560,714
Filing date: 31 October 2003 (31.10.2003)

Date of receipt at the International Bureau: 01 December 2004 (01.12.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

November 23, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/560,714

FILING DATE: *October 31, 2003*

RELATED PCT APPLICATION NUMBER: *PCT/US04/34519*

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office



Atty. Dkt. No. 085747-0302



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peter BACH et al.
Title: NOVEL COMPOUNDS II
Appl. No.: Unknown
Filing Date: October 31, 2003
Examiner: Unknown
Art Unit: Unknown

UTILITY PATENT APPLICATION
TRANSMITTAL

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is the nonprovisional utility patent application of:

Peter BACH
Udo BAUER
Karolina NILSSON
Andreas WALLBERG

☐ Applicant claims small entity status under 37 CFR 1.27.

Enclosed are:

- ☒ Specification, Claim(s), and Abstract (22 pages).
- ☐ Declaration and Power of Attorney (___ pages).
- ☐ Assignment of the invention to AstraZeneca and NPS Pharmaceuticals, Inc..
- ☒ Application Data Sheet (37 CFR 1.76).

103103

16179 U.S. PTO

Atty. Dkt. No. 085747-0302

The filing fee is calculated below:

	Claims as Filed	Included in Basic Fee	Extra Claims	Rate	Fee Totals
Basic Fee				\$770.00	\$770.00
Total	15	- 20	= 0	x \$18.00	= \$0.00
Claims:					
Independ	7	- 3	= 4	x \$86.00	= \$344.00
ents:					
If any Multiple Dependent Claim(s) present:				+ \$290.00	= \$290.00
Surcharge under 37 CFR 1.16(e) for late filing				+ \$130.00	= \$130.00
of Executed Declaration and late payment of					
filing fee					
				SUBTOTAL:	= \$1534.00
[] Small Entity Fees Apply (subtract 1/2 of above):					= \$0.00
				TOTAL FILING FEE:	= \$1,534.00

- [] A check in the amount of \$0.00 to cover the filing fee is enclosed.
- [X] The required filing fees are not enclosed but will be submitted in response to the Notice to File Missing Parts of Application.
- [] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully-submitted,

M. L. L. M. A. L. L.

Date Oct 31, 2003

By Reg No. 34,717

FOLEY & LARDNER
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

for Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

NOVEL COMPOUNDS II

Field of the invention

5 The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising said novel compounds.

Background of the invention

10

The metabotropic glutamate receptors (mGluR) are G-protein coupled receptors that are involved in the regulation and activity of many synapses in the central nervous system (CNS). Eight metabotropic glutamate receptor subtypes have been identified and are subdivided into three groups based on sequence similarity. Group I consists of mGluR1 and mGluR5. These receptors activate phospholipase C and increase neuronal excitability. 15 Group II, consisting of mGluR2 and mGluR3 as well as group III, consisting of mGluR4, mGluR6, mGluR7 and mGluR8 are capable of inhibiting adenylyl cyclase activity and reduce synaptic transmission. Several of the receptors also exist in various isoforms, occurring by alternative splicing (*Chen, C-Y et al., Journal of Physiology (2002), 538.3, pp. 773-786; Pin, J-P et al., European Journal of Pharmacology (1999), 375, pp. 277-294; Bräuner-Osborne, H et al. Journal of Medicinal Chemistry (2000), 43, pp. 2609-2645; Schoepp, D.D, Jane D.E. Monn J.A. Neuropharmacology (1999), 38, pp. 1431-1476.*) 20

The lower esophageal sphincter (LES) is prone to relaxing intermittently. As a consequence, fluid from the stomach can pass into the esophagus since the mechanical 25 barrier is temporarily lost at such times, an event hereinafter referred to as "reflux".

Gastro-esophageal reflux disease (GERD) is the most prevalent upper gastrointestinal tract disease. Current pharmacotherapy aims at reducing gastric acid secretion, or at neutralizing acid in the esophagus. The major mechanism behind reflux has been considered to depend 30 on a hypotonic lower esophageal sphincter. However, e.g. *Holloway & Dent (1990)*


Gastroenterol. Clin. N. Amer. 19, pp. 517-535, has shown that most reflux episodes occur during transient lower esophageal sphincter relaxations (TLESRs), i.e. relaxations not triggered by swallows. It has also been shown that gastric acid secretion usually is normal in patients with GERD.

5

The problem underlying the present invention was to find new compounds useful in the treatment of GERD.

WO 01/16121 A1 discloses a compound A-L-B, where


10 A is a 5-, 6- or 7-membered heterocycle



L is an alkenylene, alkynylene or azo; and

B is a hydrocarbyl; cyclohydrocarbyl; heterocycle (optionally containing one or more double bonds); or aryl. These compounds have been described as being useful in inter alia
 15 cerebral ischemia, chronic neurodegeneration, psychiatric disorders, epilepsy and diseases of the pulmonary system as well as the cardiovascular system.

WO 99/02497 A2 discloses compounds of the formula




20

wherein X may be an alkenylene or an alkynylene bonded via vicinal unsaturated carbon atoms, or an azo group; and R⁵ may be an aromatic or heteroaromatic group. These compounds have been described as being useful in inter alia epilepsy, cerebral ischemia and Alzheimer's disease.

25

Outline of the invention

The present invention is directed to novel compounds according to the general formula I:



wherein

R^1 is selected from hydrogen, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, aryl and heteroaryl, wherein
 10 the aryl or heteroaryl may be substituted by C_1 - C_4 alkyl;

R^2 is selected from hydrogen and C_1 - C_4 alkyl;

R^3 is selected from hydrogen, C_1 - C_4 alkyl, F, CF_3 , CHF_2 and CH_2F ;

R^4 is selected from hydrogen, F, CF_3 , CHF_2 , CH_2F and CH_3 ;

R^5 is selected from hydrogen and F;

15 R^6 is selected from hydrogen and F;

Q is NH or NCH_3 , optionally substituted by C_1 - C_4 alkyl.

Y^1 is selected from hydrogen, halogen, nitrile, C_1 - C_4 alkoxy, and C_1 - C_4 alkyl;

Y^2 is selected from hydrogen, halogen, nitrile, C_1 - C_4 alkoxy, and C_1 - C_4 alkyl;

Y^3 is selected from hydrogen, halogen, nitrile, C_1 - C_4 alkoxy, and C_1 - C_4 alkyl;

20 as well as pharmaceutically acceptable salts, hydrates, isoforms and/or optical isomers thereof.

The general terms used in the definition of formula I have the following meanings:

Halogen is chloro, fluoro, bromo or iodo.

C₁-C₄ alkyl is a straight or branched alkyl group, each independently containing 1, 2, 3 or 4 carbon atoms, for example methyl, ethyl, n-propyl, n-butyl or isopropyl. In one
5 embodiment, the alkyl groups may contain one or more heteroatoms selected from O, N and S. Examples of such groups are methyl-ethylether, methyl-ethylamine and methyl-thiomethyl.

Cycloalkyl is a cyclic alkyl, each independently containing 3, 4, 5 or 6 carbon atoms such
10 as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

C₁-C₄ alkoxy is an alkoxy group containing 1, 2, 3 or 4 carbon atoms, such as methoxy, ethoxy, n-propoxy, n-butoxy or isopropoxy.

15 The herein used term aryl means aromatic rings with 6-14 carbon atoms including both single rings and polycyclic compounds, such as phenyl, benzyl or naphthyl.

The term heteroaryl as used herein means aromatic rings with 5-14 carbon atoms, including both single rings and polycyclic compounds, such as imidazopyridine, in which
20 one or several of the ring atoms is either oxygen, nitrogen or sulphur, such as furanyl or thiophenyl.

Within the scope of the invention are also pharmaceutically acceptable salts of the compounds of formula I as well as isomers, hydrates and isoforms thereof.

25 Pharmaceutically acceptable salts of the compound of formula I are also within the scope of the present invention. Such salts are for example salts formed with mineral acids such as hydrochloric acid; alkali metal salts such as sodium or potassium salts; or alkaline earth metal salts such as calcium or magnesium salts.

30

The novel compounds according to the present invention are useful in therapy. In one aspect of the invention said compounds are useful for the inhibition of transient lower esophageal sphincter relaxations (TLESRs) and thus for treatment or prevention of gastro-esophageal reflux disorder (GERD). In further embodiments, the compounds according to the present invention are useful for the prevention of reflux, treatment or prevention of regurgitation, treatment or prevention of asthma, treatment or prevention of laryngitis, treatment or prevention of lung disease and for the management of failure to thrive.

A further aspect of the invention is the use of a compound according to formula I, for the manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxations, for the treatment or prevention of GERD, for the prevention of reflux, for the treatment or prevention of regurgitation, treatment or prevention of asthma, treatment or prevention of laryngitis, treatment or prevention of lung disease and for the management of failure to thrive.

Still a further aspect of the invention is a method for the treatment of any one of the conditions mentioned above, whereby a pharmaceutically effective amount of a compound according to formula I above, is administered to a subject suffering from said condition(s).

In one aspect of the invention, the compounds of formula I are useful for the treatment and/or prevention of acute and chronic neurological and psychiatric disorders, anxiety and chronic and acute pain disorders. In a further aspect, said compounds are useful for the prevention and/or treatment of pain related to migraine, inflammatory pain, neuropathic pain disorders such as diabetic neuropathies, arthritis and rheumatoid diseases, low back pain, post-operative pain and pain associated with various conditions including cancer, angina, renal or biliary colic, menstruation, migraine and gout.

The term "isomers" is herein defined as compounds of formula I, which differ by the position of their functional groups and/or orientation. By "orientation" is meant stereoisomers, diastereoisomers, regioisomers and enantiomers.

The term "isoforms" as used herein is defined as compounds of formula I which differ by their crystal lattice, such as crystalline compounds and amorphous compounds.


- 5 The wording "TLESR", transient lower esophageal sphincter relaxations, is herein defined in accordance with *Mittal, R.K., Holloway, R.H., Penagini, R., Blackshaw, L.A., Dent, J., 1995; Transient lower esophageal sphincter relaxation. Gastroenterology 109, pp. 601-610.*
- 10 The wording "reflux" is defined herein as fluid from the stomach being able to pass into the esophagus, since the mechanical barrier is temporarily lost at such times.

The wording "GERD", gastro-esophageal reflux disease, is defined herein in accordance with *van Heerwarden, M.A., Smout A.J.P.M., 2000; Diagnosis of reflux disease. Baillière's Clin. Gastroenterol. 14, pp. 759-774.*

15


Methods of preparation

- First, a Sonogashira coupling (*Tetrahedron Letters* 1975, 50, 4467, S. Thorand, N. Krause
20 *J. Org. Chem.*, **1998**, 63, 8551-8553, M. Erdélyi, A. Gogoll, *J. Org. Chem.*, **2001**, 66, 4165-4169) of the aryl bromide A and the alcohol B in the presence of a base such as triethyl amine at room temperature to 60 °C gives the alcohol C which is then converted into the mesylate D with methanesulfonyl chloride in triethyl amine at about -20 to 0°C. The mesylate of the primary alcohol is isolated and characterised, while those of the
25 secondary alcohols are made in situ. Finally, the respective mesylate is reacted with primary or secondary amines to generate product (I) (Scheme 4).



SCHEME 1

In those cases where the alcohol B is not commercially available with desired R¹/R²- groups, the product (I) is formed by an alternative route (scheme 2): first the aryl bromide A is coupled with ethynyl(trimethyl)silane F via Sonogashira coupling at 60 °C in triethyl amine to give product G. Deprotection of G at room temperature with potassium carbonate in methanol gives terminal alkyne H, which is deprotonated with lithium hexamethyldisilazide in THF at - 78 °C. At - 78 °C an aldehyde or ketone is added and the reaction mixture is allowed to reach room temperature and kept at that temperature for the appropriate time to form the alcohol I. Having isolated I, the mesylate J is formed in situ with methanesulfonyl chloride and triethyl amine, either at room temperature or with cooling. Subsequently an amine is added and the reaction mixture is stirred at room temperature for the appropriate time to form product (I).



SCHEME 2

In the schemes 1 and 2 above, $R^1, R^2, R^3, R^4, R^5, R^6, Y^1, Y^2$ and Y^3 are defined as for the compounds of formula I above.

5

Experimental details

DCM is dried over 3\AA molecular sieves. THF was distilled from Na/benzophenone just prior to use. All reactions are run under a nitrogen atmosphere. All glassware is dried in $150^\circ C$ for at least two hours prior to its use. Phase separators from International Sorbent Technology (IST) are used. Purification by chromatography is done either on silica gel 60 (0.040-0.063 mm), or by reverse phase chromatography with a C8 column. All NMR spectra are measured in δ -chloroform.

2-bromo-6-methylpyridine is commercially available from Aldrich, $(\text{PPh}_3)_2\text{PdCl}_2$ from Avacado, $\text{Pd}(\text{OAc})_2$ from Aldrich and CuI from Fluka. If not stated otherwise, the chemicals used are commercially available and are used as such without further purification.

5

Pharmaceutical formulations

For clinical use, the compounds of formula I are in accordance with the present invention suitably formulated into pharmaceutical formulations for oral administration. Also rectal, parenteral or any other route of administration may be contemplated to the skilled man in the art of formulations. Thus, the compounds of formula I are formulated with at least one pharmaceutically and pharmacologically acceptable carrier or adjuvant. The carrier may be in the form of a solid, semi-solid or liquid diluent.

15 In the preparation of oral pharmaceutical formulations in accordance with the invention, the compound of formula I to be formulated is mixed with solid, powdered ingredients such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture is then processed into granules or compressed into tablets.

Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Hard gelatine capsules may contain the active compound in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatine.

Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance(s) mixed with a neutral fat base; (ii) in the form of a

30

gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil, or other suitable vehicle for gelatine rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.

5

Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions, containing the active compound and the remainder of the formulation consisting of sugar or sugar alcohols, and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethyl cellulose or other thickening agent. Liquid preparations for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.

15 Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent extemporaneously before use.

20

In one aspect of the present invention, the compounds of formula I may be administered once or twice daily, depending on the severity of the patient's condition.

A typical daily dose of the compounds of formula I is from 0.1 – 10 mg per kg body weight of the subject to be treated, but this will depend on various factors such as the route of administration, the age and weight of the patient as well as of severity of the patient's condition.


25

Examples

Method G

Example 1

5 Preparation of 3-(6-methylpyridin-2-yl)prop-2-yn-1-ol (compound 16):




To 2-bromo-6-methylpyridine (1.72 g, 0.01 mol) was added $(PPh_3)_2PdCl_2$ (0.116 g, 0.2 mmol, 0.02 eq.) and CuI (0.063 g, 0.3 mmol, 0.03 eq.) at 0 °C under nitrogen, followed by prop-2-yn-1-ol (2.24 g, 2.33 mL, 0.4 mol, 4.0 eq.) and triethylamine (1.50 mL). The reaction mixture was allowed to reach room temperature and then heated at 60 °C for 3.5 h. Then the reaction mixture was added to water (10 mL) and the pH was adjusted to 6-7 with 2 M HCl. The water phase was extracted with DCM (3 x 10 mL) and the combined organic phases were dried with sodium sulphate and evaporated. This gave 1.719 g crude product. 1.098 g hereof was subjected to flash chromatography on silica gel with pentane/EtOAc, first 1:1, then 1:2, finally 1:3, as eluent. This gave 0.578 g product. ^{13}C NMR (75 MHz): 157.7, 141.1, 136.2, 123.7, 122.3, 88.4, 83.0, 49.9, 23.5.

20 *Method H*

Example 2

Preparation of 3-(6-methylpyridin-2-yl)prop-2-yn-1-yl methanesulfonate (compound 17):



3-(6-methylpyridin-2-yl)prop-2-yn-1-ol (0.300 g, 2.04 mmol) was dissolved in DCM (10 mL) under nitrogen over 5-10 min. The solution was cooled to -20 °C (cooling bath: acetone + pieces of dry ice). Triethylamine (0.268 g, 0.37 mL, 0.27 mmol, 1.30 eq.) was added. Methanesulfonyl chloride (0.280 g, 0.19 mL, 0.24 mmol, 1.2 eq.) in DCM (1.5 mL) was added over 3 min. The reaction mixture was stirred at -18 to -22 °C for 1h after which time LC/MS only showed product. Water (10 mL) was added. The organic phase was separated and the water phase was extracted with DCM (3 x 10 mL). The organic phases were pooled, dried with magnesium sulphate and evaporated. This gave 0.450 g (yield: 98 %) as a yellow oil.


¹H NMR (300 MHz): 7.61 (t, J = 7.7 Hz, 1H), 7.31 (d, J = 7.7 Hz, 1H), 7.19 (d, J = 7.7 Hz, 1H), 5.10 (s, 2H), 3.18 (s, 3H), 2.58 (s, 3H).

¹³C NMR (75 MHz): 158.9, 140.2, 136.8, 124.5, 123.8, 87.8, 80.7, 57.7, 38.9, 24.2.

Method I

Example 3

Preparation of N-[3-(6-methylpyridin-2-yl)prop-2-yn-1-yl]aniline (compound 18):



20

3-(6-methylpyridin-2-yl)prop-2-yn-1-yl methanesulfonate (0.044 g, 0.195 mmol) was stirred with aniline (0.182 g, 0.180 mL, 1.95 mmol, 10.0 eq.) in triethylamine (0.372 g, 0.270 mL, 10.0 eq.) at room temperature for 1.5h. According to LC/MS no mesylate remained after that time.

25

The mixture was evaporated and purified by reverse phase column chromatography. Yield: 0.017 g (40%).

¹H NMR (500 MHz): 7.50 (t, *J* = 7.7 Hz, 1H), 7.28-7.16 (m, overlap with CDCl₃, 3H), 7.08 (d, *J* = 7.8 Hz, 1H), 6.82-6.69 (m, 3H), 4.18 (s, 2H), 2.54 (s, 3H).

¹³C NMR (125 MHz): 158.6, 146.7, 141.9, 136.1, 129.0, 124.0, 122.5, 118.3, 113.4, 86.0, 82.7, 34.4, 24.5.


5

Example 19

Preparation of *N*-benzyl-3-(6-methylpyridin-2-yl)prop-2-yn-1-amine (compound 19):

prepared according to method I above, with benzylamine as starting material

10



Yield: 23 % after reverse phase chromatography.


¹H NMR (500 MHz): 7.54 (t, *J* = 7.8 Hz, 1H), 7.38-7.32 (m, 4H), 7.29-7.23 (m, 2H), 7.09 (d, *J* = 7.8 Hz, 1H), 3.95 (s, 2H), 3.68 (s, 2H), 2.56 (s, 3H), 1.80 (br, 2H, acetate).

15

Method J

Example 20

20 Preparation of *N*-methyl-*N*-[3-(6-methylpyridin-2-yl)prop-2-yn-1-yl]aniline (compound 20):



3-(6-methylpyridin-2-yl)prop-2-yn-1-yl methanesulfonate (0.042 g, 0.19 mmol) was stirred with N-methyl-aniline (0.040g, 0.040 mL, 0.37 mmol, 2.0 eq.) in triethylamine (0.20 mL) at room temperature for 21h. According to LC/MS no mesylate remained after that time.

The mixture was evaporated and purified by reverse phase column chromatography. Yield: 3.5 mg (7 %).

¹H NMR (500 MHz): 7.48 (t, J = 7.8 Hz, 1H), 7.29-7.25 (m, 2H), 7.16 (d, J = 7.8 Hz, 1H), 7.06 (d, J = 7.8 Hz, 1H), 6.91 (m, 2H), 6.81 (t, J = 7.4 Hz, 1H), 4.30 (s, 2H), 3.05 (s, 3H), 2.53 (s, 3H), 1.68 (br, 3H, acetate).

Biological evaluation

Functional assessment of mGluR5 antagonism in cell lines expressing mGluR5d

The properties of the compounds of the invention can be analyzed using standard assays for pharmacological activity. Examples of glutamate receptor assays are well known in the art as described in for example Aramori *et al.*, *Neuron* 8:757 (1992), Tanabe *et al.*, *Neuron* 8:169 (1992), Miller *et al.*, *J. Neuroscience* 15: 6103 (1995), Balazs, *et al.*, *J.*

Neurochemistry 69:151 (1997). The methodology described in these publications is incorporated herein by reference. Conveniently, the compounds of the invention can be studied by means of an assay (FLIPR) that measures the mobilization of intracellular calcium, [Ca²⁺]_i in cells expressing mGluR5 or another assay (IP3) that measures inositol phosphate turnover.

FLIPR Assay

Cells expressing human mGluR5d as described in WO97/05252 are seeded at a density of 100,000 cells per well on collagen coated clear bottom 96-well plates with black sides and experiments are done 24 h following seeding. All assays are done in a buffer containing 127 mM NaCl, 5 mM KCl, 2 mM MgCl₂, 0.7 mM NaH₂PO₄, 2 mM CaCl₂, 0.422 mg/ml NaHCO₃, 2.4 mg/ml HEPES, 1.8 mg/ml glucose and 1 mg/ml BSA Fraction IV (pH 7.4). Cell cultures in the 96-well plates are loaded for 60 minutes in the above mentioned buffer

containing 4 μM of the acetoxymethyl ester form of the fluorescent calcium indicator fluo-3 (Molecular Probes, Eugene, Oregon) in 0.01% pluronic acid (a proprietary, non-ionic surfactant polyol – CAS Number 9003-11-6). Following the loading period the fluo-3 buffer is removed and replaced with fresh assay buffer. FLIPR experiments are done using a laser setting of 0.800 W and a 0.4 second CCD camera shutter speed with excitation and emission wavelengths of 488 nm and 562 nm, respectively. Each experiment is initiated with 160 μl of buffer present in each well of the cell plate. A 40 μl addition from the antagonist plate was followed by a 50 μL addition from the agonist plate. A 90 second interval separates the antagonist and agonist additions. The fluorescence signal is sampled 50 times at 1 second intervals followed by 3 samples at 5 second intervals immediately after each of the two additions. Responses are measured as the difference between the peak height of the response to agonist, less the background fluorescence within the sample period. IC_{50} determinations are made using a linear least squares fitting program.

IP3 Assay

An additional functional assay for mGluR5d is described in WO97/05252 and is based on phosphatidylinositol turnover. Receptor activation stimulates phospholipase C activity and leads to increased formation of inositol 1,4,5-triphosphate (IP_3).

GHEK stably expressing the human mGluR5d are seeded onto 24 well poly-L-lysine coated plates at 40×10^4 cells /well in media containing 1 μCi /well [^3H] myo-inositol. Cells were incubated overnight (16 h), then washed three times and incubated for 1 h at 37°C in HEPES buffered saline (146 mM NaCl, 4.2 mM KCl, 0.5 mM MgCl_2 , 0.1% glucose, 20 mM HEPES, pH 7.4) supplemented with 1 unit/ml glutamate pyruvate transaminase and 2 mM pyruvate. Cells are washed once in HEPES buffered saline and pre-incubated for 10 min in HEPES buffered saline containing 10 mM LiCl. Compounds are incubated in duplicate at 37°C for 15 min, then either glutamate (80 μM) or DHPG (30 μM) is added and incubated for an additional 30 min. The reaction is terminated by the addition of 0.5 ml perchloric acid (5%) on ice, with incubation at 4°C for at least 30 min. Samples are collected in 15 ml polypropylene tubes and inositol phosphates are separated using ion-exchange resin (Dowex AG1-X8 formate form, 200-400 mesh, BIORAD)

columns. Inositol phosphate separation was done by first eluting glycerophosphatidyl inositol with 8 ml 30 mM ammonium formate. Next, total inositol phosphates is eluted with 8 ml 700 mM ammonium formate / 100 mM formic acid and collected in scintillation vials. This eluate is then mixed with 8 ml of scintillant and [^3H] inositol incorporation is determined by scintillation counting. The dpm counts from the duplicate samples are plotted and IC_{50} determinations are generated using a linear least squares fitting program.

Abbreviations

BSA	Bovine Serum Albumin
10 CCD	Charge Coupled Device
CRC	Concentration Response Curve
DHPG	3,5-dihydroxyphenylglycine
DPM	Disintegrations per Minute
EDTA	Ethylene Diamine Tetraacetic Acid
15 FLIPR	Fluorometric Imaging Plate reader
GHEK	GLAST-containing Human Embryonic Kidney
GLAST	glutamate/aspartate transporter
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (buffer)
IP_3	inositol triphosphate

Generally, the compounds are active in the assay above with IC_{50} values less than 10 000 nM. In one aspect of the invention, the IC_{50} value is less than 1 μM . In a further aspect of the invention, the IC_{50} value is less than 100 nM.

Screening for compounds active against TLESR

Adult Labrador retrievers of both genders, trained to stand in a Pavlov sling, are used. Mucosa-to-skin esophagostomies are formed and the dogs are allowed to recover completely before any experiments are done.

Motility measurement


In brief, after fasting for approximately 17 h with free supply of water, a multilumen sleeve/sidehole assembly (Dentsleeve, Adelaide, South Australia) is introduced through the esophagostomy to measure gastric, lower esophageal sphincter (LES) and esophageal pressures. The assembly is perfused with water using a low-compliance manometric perfusion pump (Dentsleeve, Adelaide, South Australia). An air-perfused tube is passed in the oral direction to measure swallows, and an antimony electrode monitored pH, 3 cm above the LES. All signals are amplified and acquired on a personal computer at 10 Hz.

When a baseline measurement free from fasting gastric/LES phase III motor activity has been obtained, placebo (0.9% NaCl) or test compound is administered intravenously (i.v., 0.5 ml/kg) in a foreleg vein. Ten min after i.v. administration, a nutrient meal (10% peptone, 5% D-glucose, 5% Intralipid, pH 3.0) is infused into the stomach through the central lumen of the assembly at 100 ml/min to a final volume of 30 ml/kg. The infusion of the nutrient meal is followed by air infusion at a rate of 500 ml/min until an intragastric pressure of 10 ± 1 mmHg is obtained. The pressure is then maintained at this level throughout the experiment using the infusion pump for further air infusion or for venting air from the stomach. The experimental time from start of nutrient infusion to end of air insufflation is 45 min. The procedure has been validated as a reliable means of triggering TLESRs.

TLESRs is defined as a decrease in lower esophageal sphincter pressure (with reference to intragastric pressure) at a rate of >1 mmHg/s. The relaxation should not be preceded by a pharyngeal signal ≤ 2 s before its onset in which case the relaxation is classified as swallow-induced. The pressure difference between the LES and the stomach should be less than 2 mmHg, and the duration of the complete relaxation longer than 1 s.

Claims

1. A compound of formula I



wherein

R^1 is selected from hydrogen, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, aryl and heteroaryl,

wherein the aryl or heteroaryl may be substituted by C_1 - C_4 alkyl;

R^2 is selected from hydrogen and C_1 - C_4 alkyl;

R^3 is selected from hydrogen, C_1 - C_4 alkyl, F, CF_3 , CHF_2 and CH_2F ;

R^4 is selected from hydrogen, F, CF_3 , CHF_2 , CH_2F and CH_3 ;

R^5 is selected from hydrogen and F;

R^6 is selected from hydrogen and F;

Q is NH or NCH_3 , optionally substituted by C_1 - C_4 alkyl.

Y^1 is selected from hydrogen, halogen, nitrile, C_1 - C_4 alkoxy, and C_1 - C_4 alkyl;

Y^2 is selected from hydrogen, halogen, nitrile, C_1 - C_4 alkoxy, and C_1 - C_4 alkyl;

Y^3 is selected from hydrogen, halogen, nitrile, C_1 - C_4 alkoxy, and C_1 - C_4 alkyl;

as well as pharmaceutically acceptable salts, hydrates, isoforms and/or optical isomers thereof.

2. A compound according to formula I of claim 1, wherein

R^1 is hydrogen or C_1 - C_3 alkyl;

R^2 is hydrogen;

R³ is selected from hydrogen and methyl;

R⁴ is hydrogen;

R⁵ is hydrogen;

R⁶ is hydrogen;

Q is NH or NCH₃;

Y¹ is selected from hydrogen, chloro, C₁-C₂ alkoxy, and C₁-C₂ alkyl; and

Y² is selected from hydrogen, chloro, C₁-C₂ alkoxy, and C₁-C₂ alkyl; and

Y³ is hydrogen.

3. A compound according to claim 1 selected from *N*-benzyl-3-(6-methylpyridin-2-yl)prop-2-yn-1-amine, *N*-benzyl-3-(6-methylpyridin-2-yl)prop-2-yn-1-amine and *N*-methyl-*N*-[3-(6-methylpyridin-2-yl)prop-2-yn-1-yl]aniline.

4. A compound according to any one of claims 1-3 for use in therapy.


5. A compound according to claim 4, wherein the therapy is treatment or prevention of gastroesophageal reflux disease.

6. Use of a compound of formula I, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxations.


7. Use of a compound of formula I, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for treatment or prevention of gastroesophageal reflux disease.

8. A pharmaceutical composition comprising a compound of formula I as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.


9. A process for the preparation of a compound of formula I, whereby a coupling reaction of the aryl bromide A




and the alcohol B



is performed in the presence of a base such as triethyl amine, giving the alcohol C



which is then converted into the mesylate D



and reacted with primary or secondary amines, and wherein

R^1 is selected from hydrogen, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, aryl and heteroaryl,

wherein the aryl or heteroaryl may be substituted by C_1 - C_4 alkyl;

R^2 is selected from hydrogen and C_1 - C_4 alkyl;

R^3 is selected from hydrogen, C_1 - C_4 alkyl, F, CF_3 , CHF_2 and CH_2F ;

R^4 is selected from hydrogen, F, CF_3 , CHF_2 , CH_2F and CH_3 ;

R^5 is selected from hydrogen and F;

R^6 is selected from hydrogen and F.


- 5 10. A method for the inhibition of transient lower esophageal sphincter relaxations
whereby an effective amount of a compound of formula I is administered to a
subject in need of such inhibition.
- 10 11. A method for the treatment or prevention of gastroesophageal reflux disease,
whereby an effective amount of a compound of formula I is administered to a
subject in need of such treatment or prevention.

Abstract

The present invention is directed to novel compounds of formula I, to a process for their preparation, their use and pharmaceutical compositions comprising the novel compounds.

The novel compounds are useful in therapy, and in particular for the treatment of

5 gastroesophageal reflux disease (GERD).



10 wherein

R^1 is selected from hydrogen, C_1 - C_4 alkyl, C_3 - C_6 cycloalkyl, aryl and heteroaryl, wherein the aryl or heteroaryl may be substituted by C_1 - C_4 alkyl;

R^2 is selected from hydrogen and C_1 - C_4 alkyl;

R^3 is selected from hydrogen, C_1 - C_4 alkyl, F, CF_3 , CHF_2 and CH_2F ;

15 R^4 is selected from hydrogen, F, CF_3 , CHF_2 , CH_2F and CH_3 ;

R^5 is selected from hydrogen and F;

R^6 is selected from hydrogen and F;

Q is NH or NCH_3 , optionally substituted by C_1 - C_4 alkyl.

Y^1 is selected from hydrogen, halogen, nitrile, C_1 - C_4 alkoxy, and C_1 - C_4 alkyl;

20 Y^2 is selected from hydrogen, halogen, nitrile, C_1 - C_4 alkoxy, and C_1 - C_4 alkyl;

Y^3 is selected from hydrogen, halogen, nitrile, C_1 - C_4 alkoxy, and C_1 - C_4 alkyl;

as well as pharmaceutically acceptable salts, hydrates, isoforms and/or optical isomers thereof.

Application Data Sheet

Application Information

Application Type::	Regular
Subject Matter::	Utility
Suggested classification::	
Suggested Group Art Unit::	
CD-ROM or CD-R?::	None
Computer Readable Form (CRF)?::	No
Title::	NOVEL COMPOUNDS II
Attorney Docket Number::	085747-0302
Request for Early Publication?::	No
Request for Non-Publication?::	No
Suggested Drawing Figure::	
Total Drawing Sheets::	
Small Entity?::	No
Petition included?::	No
Secrecy Order in Parent Appl.?::	No

Applicant Information

Applicant Authority Type::	Inventor
Primary Citizenship Country::	US
Status::	Full Capacity
Given Name::	Peter
Family Name::	BACH
City of Residence::	Molndal
Country of Residence::	Sweden
Street of mailing address::	AstraZeneca R&D Molndal 83 Molndal SE-431
Country of mailing address::	Sweden
Applicant Authority Type::	Inventor
Primary Citizenship Country::	US
Status::	Full Capacity

Given Name:: Udo
Family Name:: BAUER
City of Residence:: Molndal
Country of Residence:: Sweden
Street of mailing address:: AstraZeneca R&D Molndal
83 Molndal
SE-431
Country of mailing address:: Sweden

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Karolina
Family Name:: NILSSON
City of Residence:: Molndal
Country of Residence:: Sweden
Street of mailing address:: AstraZeneca R&D Molndal
83 Molndal
SE-431
Country of mailing address:: Sweden

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Andreas
Family Name:: WALLBERG
City of Residence:: Molndal
Country of Residence:: Sweden
Street of mailing address:: AstraZeneca R&D Molndal
83 Molndal
SE-431
Country of mailing address:: Sweden

Correspondence Information

Correspondence Customer Number:: 22428
E-Mail address:: PTOMailWashington@Foley.com

Representative Information

Representative Customer Number::	22428	
-----------------------------------------	-------	--

Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::

Foreign Priority Information

Country::	Application number::	Filing Date::	Priority Claimed::

Assignee Information

Assignee name:: AstraZeneca and NPS Pharmaceuticals, Inc.